Literature DB >> 28004346

Bioavailability and Bioequivalence Aspects of Oral Modified-Release Drug Products.

Rong Wang1, Dale P Conner2, Bing V Li3.   

Abstract

Oral modified-release (MR) products are dosage forms administered through the mouth and designed to release drug in a controlled manner to achieve maximum efficacy, minimal side effects, and better patient compliance. With significant progress in pharmaceutical technologies and favored therapeutic benefit, more and more oral MR products including the generic versions of these products are being developed, marketed, and used in the USA. Because different types of MR products may exhibit unique drug release modes and specific pharmacokinetic profiles, a better understanding of the regulation and evaluation of these generic MR products can help development and marketing of generic MR products that are therapeutically equivalent to the corresponding reference product. This review summarizes the general regulatory requirements for establishing bioequivalence between generic and reference oral MR products. In addition, some special regulatory considerations for bioequivalence evaluation are highlighted with examples of specific oral MR drug products.

Entities:  

Keywords:  bioavailability; bioequivalence; modified release; oral dosage form

Mesh:

Substances:

Year:  2016        PMID: 28004346     DOI: 10.1208/s12248-016-0025-9

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  11 in total

1.  Investigation on the need of multiple dose bioequivalence studies for prolonged-release generic products.

Authors:  Alfredo García-Arieta; Susana Morales-Alcelay; Marta Herranz; José María de la Torre-Alvarado; Antonio Blázquez-Pérez; Ma Luisa Suárez-Gea; Covadonga Alvarez
Journal:  Int J Pharm       Date:  2011-11-20       Impact factor: 5.875

2.  Use of partial AUC to demonstrate bioequivalence of Zolpidem Tartrate Extended Release formulations.

Authors:  Robert A Lionberger; Andre S Raw; Stephanie H Kim; Xinyuan Zhang; Lawrence X Yu
Journal:  Pharm Res       Date:  2012-01-26       Impact factor: 4.200

Review 3.  International guidelines for bioequivalence of systemically available orally administered generic drug products: a survey of similarities and differences.

Authors:  Barbara Davit; April C Braddy; Dale P Conner; Lawrence X Yu
Journal:  AAPS J       Date:  2013-07-03       Impact factor: 4.009

4.  In vitro dissolution profile comparison--statistics and analysis of the similarity factor, f2.

Authors:  V P Shah; Y Tsong; P Sathe; J P Liu
Journal:  Pharm Res       Date:  1998-06       Impact factor: 4.200

5.  Dissolution testing for generic drugs: an FDA perspective.

Authors:  Om Anand; Lawrence X Yu; Dale P Conner; Barbara M Davit
Journal:  AAPS J       Date:  2011-04-09       Impact factor: 4.009

Review 6.  Implementation of a reference-scaled average bioequivalence approach for highly variable generic drug products by the US Food and Drug Administration.

Authors:  Barbara M Davit; Mei-Ling Chen; Dale P Conner; Sam H Haidar; Stephanie Kim; Christina H Lee; Robert A Lionberger; Fairouz T Makhlouf; Patrick E Nwakama; Devvrat T Patel; Donald J Schuirmann; Lawrence X Yu
Journal:  AAPS J       Date:  2012-09-13       Impact factor: 4.009

Review 7.  Metrics for the evaluation of bioequivalence of modified-release formulations.

Authors:  Laszlo Endrenyi; Laszlo Tothfalusi
Journal:  AAPS J       Date:  2012-08-22       Impact factor: 4.009

8.  Evaluation of bioequivalence of highly variable drugs using Monte Carlo simulations. I. Estimation of rate of absorption for single and multiple dose trials using Cmax.

Authors:  A A el-Tahtawy; A J Jackson; T M Ludden
Journal:  Pharm Res       Date:  1995-11       Impact factor: 4.200

9.  Comparison of single and multiple dose pharmacokinetics using clinical bioequivalence data and Monte Carlo simulations.

Authors:  A A el-Tahtawy; A J Jackson; T M Ludden
Journal:  Pharm Res       Date:  1994-09       Impact factor: 4.200

10.  The impact of lag time on the estimation of pharmacokinetic parameters. I. One-compartment open model.

Authors:  N G Nerella; L H Block; P K Noonan
Journal:  Pharm Res       Date:  1993-07       Impact factor: 4.200

View more
  2 in total

Review 1.  Industry Perspective on Standardizing Food-Effect Studies for New Drug Development.

Authors:  Patrick J Marroum; Silpa Nuthalapati; Apurvasena Parikh; Mohamad Shebley; David Hoffman; Jiuhong Zha; Amit Khatri; Walid M Awni
Journal:  Clin Pharmacokinet       Date:  2018-08       Impact factor: 6.447

2.  Network Pharmacology-Based Strategy for Predicting Active Ingredients and Potential Targets of Gegen Qinlian Decoction for Rotavirus Enteritis.

Authors:  Peicheng Zhong; Lijun Song; Mengyue Gao; Xiaotong Wang; Wenpan Tan; Huanqian Lu; Qian Lan; Zuyi Zhao; Wenchang Zhao
Journal:  Evid Based Complement Alternat Med       Date:  2020-07-29       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.